These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 20831917)

  • 21. Cloning, protein expression and immunogenicity of HBs-murine IL-18 fusion DNA vaccine.
    Channarong S; Mitrevej A; Sinchaipanid N; Usuwantim K; Kulkeaw K; Chaicumpa W
    Asian Pac J Allergy Immunol; 2007 Dec; 25(4):233-42. PubMed ID: 18402297
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HIV-1 derived peptides fused to HBsAg affect its immunogenicity.
    Gonzalez MC; Kostrzak A; Guetard D; Pniewski T; Sala M
    Virus Res; 2009 Dec; 146(1-2):107-14. PubMed ID: 19766153
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Kinetics of hepatitis B surface antigen-specific immune responses in acute and chronic hepatitis B or after HBs vaccination: stimulation of the in vitro antibody response by interferon gamma.
    Böcher WO; Herzog-Hauff S; Schlaak J; Meyer zum Büschenfeld KH; Löhr HF
    Hepatology; 1999 Jan; 29(1):238-44. PubMed ID: 9862872
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cationic transfersomes based topical genetic vaccine against hepatitis B.
    Mahor S; Rawat A; Dubey PK; Gupta PN; Khatri K; Goyal AK; Vyas SP
    Int J Pharm; 2007 Aug; 340(1-2):13-9. PubMed ID: 17446015
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of SV40 to immunize against hepatitis B surface antigen: implications for the use of SV40 for gene transduction and its use as an immunizing agent.
    Kondo R; Feitelson MA; Strayer DS
    Gene Ther; 1998 May; 5(5):575-82. PubMed ID: 9797861
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Humoral and cellular immune responses to hepatitis B vaccination in hepatitis B surface antigen-carrier children who cleared serum-hepatitis B surface antigen.
    Hsu HY; Chang MH; Hsieh RP; Ni YH; Chi WK
    Hepatology; 1996 Dec; 24(6):1355-60. PubMed ID: 8938161
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Revealing the potential of DNA-based vaccination: lessons learned from the hepatitis B virus surface antigen.
    Schirmbeck R; Reimann J
    Biol Chem; 2001 Apr; 382(4):543-52. PubMed ID: 11405219
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimization of immune responses induced by therapeutic vaccination with cross-reactive antigens in a humanized hepatitis B surface antigen transgenic mouse model.
    Bourgine M; Dion S; Godon O; Guillen G; Michel ML; Aguilar JC
    Virology; 2012 Aug; 430(1):10-9. PubMed ID: 22591777
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adjuvant effect of CIA07, a combination of Escherichia coli DNA fragments and modified lipopolysaccharides, on the immune response to hepatitis B virus surface antigen.
    Song ES; Park SA; Kim SH; Cho YJ; Ahn BY; Ahn BC; Lee NG
    FEMS Immunol Med Microbiol; 2007 Dec; 51(3):496-504. PubMed ID: 17877731
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Reciprocal priming-boosting role of HBsAg and DNA vaccines].
    Zhou Z; Chen WS; Zhang HH; Yao JL
    Zhonghua Gan Zang Bing Za Zhi; 2003 Apr; 11(4):212-4. PubMed ID: 12716517
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regulation of hepatitis B virus mRNA expression in a hepatitis B surface antigen transgenic mouse model by IFN-gamma-secreting T cells after DNA-based immunization.
    Mancini M; Hadchouel M; Tiollais P; Michel ML
    J Immunol; 1998 Nov; 161(10):5564-70. PubMed ID: 9820533
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vivo induction of specific cytotoxic T lymphocytes in mice and rhesus macaques immunized with DNA vector encoding an HIV epitope fused with hepatitis B surface antigen.
    Le Borgne S; Mancini M; Le Grand R; Schleef M; Dormont D; Tiollais P; Rivière Y; Michel ML
    Virology; 1998 Jan; 240(2):304-15. PubMed ID: 9454704
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Specific cellular and humoral immune responses induced by intramuscular injection of DNA vaccine containing HBV HBsAg gene in mice].
    Liu S; Tan D; Li C
    Hunan Yi Ke Da Xue Xue Bao; 1999; 24(4):313-5. PubMed ID: 12080633
    [TBL] [Abstract][Full Text] [Related]  

  • 34. DNA vaccines for prophylactic or therapeutic immunization against hepatitis B virus.
    Davis HL
    Mt Sinai J Med; 1999 Mar; 66(2):84-90. PubMed ID: 10100411
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Different antibody responses against hepatitis B surface antigen among mouse strains transfected with mutant viral DNA.
    Hasegawa K; Joh R; Iizuka A; Naritomi T; Kanai N; Ogawa M; Torii N; Hayashi N
    J Gastroenterol; 2002; 37(12):1035-41. PubMed ID: 12522535
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inducing oral immune regulation of hepatitis B virus envelope proteins suppresses the growth of hepatocellular carcinoma in mice.
    Gotsman I; Alper R; Klein A; Rabbani E; Engelhardt D; Ilan Y
    Cancer; 2002 Jan; 94(2):406-14. PubMed ID: 11900226
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immune modulator and antiviral potential of dendritic cells pulsed with both hepatitis B surface antigen and core antigen for treating chronic HBV infection.
    Akbar SM; Yoshida O; Chen S; Cesar AJ; Abe M; Matsuura B; Hiasa Y; Onji M
    Antivir Ther; 2010; 15(6):887-95. PubMed ID: 20834101
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhancing the immunogenicity of exogenous hepatitis B surface antigen-based vaccines for MHC-I-restricted T cells.
    Schirmbeck R; Reimann J
    Biol Chem; 1999 Mar; 380(3):285-91. PubMed ID: 10223330
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hepatitis B surface antigen vector delivers protective cytotoxic T-lymphocyte responses to disease-relevant foreign epitopes.
    Woo WP; Doan T; Herd KA; Netter HJ; Tindle RW
    J Virol; 2006 Apr; 80(8):3975-84. PubMed ID: 16571814
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Elimination of immunodominant epitopes from multispecific DNA-based vaccines allows induction of CD8 T cells that have a striking antiviral potential.
    Riedl P; Wieland A; Lamberth K; Buus S; Lemonnier F; Reifenberg K; Reimann J; Schirmbeck R
    J Immunol; 2009 Jul; 183(1):370-80. PubMed ID: 19542448
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.